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indirectly by electrocardiography (ECG) and by measur-
ing enzyme levels in patients undergoing primary or
repeat coronary artery bypass grafting (CABG).8,10,11
These studies documented a reduction in transfusion
requirements and found no statistically significant
increase in the prevalence of myocardial infarction in
R ecent studies have demonstrated that aprotinin, aninhibitor of certain serine proteinases1 administered
during coronary surgery, significantly reduces postopera-
tive blood loss and the need for allogeneic blood transfu-
sion.2-10 One potential adverse effect of aprotinin could
be postoperative graft occlusion. This has been studied
Objective: We examined the effects of aprotinin on graft patency, preva-
lence of myocardial infarction, and blood loss in patients undergoing
primary coronary surgery with cardiopulmonary bypass. Methods:
Patients from 13 international sites were randomized to receive intraop-
erative aprotinin (n = 436) or placebo (n = 434). Graft angiography was
obtained a mean of 10.8 days after the operation. Electrocardiograms,
cardiac enzymes, and blood loss and replacement were evaluated.
Results: In 796 assessable patients, aprotinin reduced thoracic drainage
volume by 43% (P < .0001) and requirement for red blood cell adminis-
tration by 49% (P < .0001). Among 703 patients with assessable saphe-
nous vein grafts, occlusions occurred in 15.4% of aprotinin-treated
patients and 10.9% of patients receiving placebo (P = .03). After we had
adjusted for risk factors associated with vein graft occlusion, the apro-
tinin versus placebo risk ratio decreased from 1.7 to 1.05 (90% confi-
dence interval, 0.6 to 1.8). These factors included female gender, lack of
prior aspirin therapy, small and poor distal vessel quality, and possibly
use of aprotinin-treated blood as excised vein perfusate. At United States
sites, patients had characteristics more favorable for graft patency, and
occlusions occurred in 9.4% of the aprotinin group and 9.5% of the
placebo group (P = .72). At Danish and Israeli sites, where patients had
more adverse characteristics, occlusions occurred in 23.0% of apro-
tinin- and 12.4% of placebo-treated patients (P = .01). Aprotinin did not
affect the occurrence of myocardial infarction (aprotinin: 2.9%; place-
bo: 3.8%) or mortality (aprotinin: 1.4%; placebo: 1.6%). Conclusions: In
this study, the probability of early vein graft occlusion was increased by
aprotinin, but this outcome was promoted by multiple risk factors for
graft occlusion. (J Thorac Cardiovasc Surg 1998;116:716-30)
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patients treated with aprotinin. However, 1 other study
reported an insignificant trend toward higher myocardial
infarction rates in aprotinin-treated patients having a sec-
ond CABG operation.7 Because enzyme and ECG crite-
ria provide only indirect evidence of graft closure, the
present study was designed with a sufficient sample size
to investigate angiographically whether aprotinin has
any adverse effect on graft patency in primary CABG
operations. The study also investigated the prevalence of
myocardial infarction and reassessed the effect of apro-
tinin on allogeneic transfusion requirements.
Methods
Patient selection. After institutional review committee
approval and informed consent, patients who required elec-
tive myocardial revascularization and who did not require
noncoronary procedures (eg, aneurysm resection or valve
replacement) were studied. There was no upper age limit or
gender restriction with the exception of known or suspected
pregnancy.
Excluded patients were those with known or suspected
allergy to aprotinin or radiographic contrast media or who
had received an investigational drug within the preceding 30
days. Patients with any known bleeding disorder or hemato-
logic abnormality that would require prophylactic use of
drugs to decrease transfusion requirements were excluded, as
were those who refused the use of allogeneic blood products,
who had pre-donated autologous blood, or whose preopera-
tive red blood cell (RBC) mass was so low that packed RBCs
would be included in the prime fluid for cardiopulmonary
bypass (CPB). Patients who had a previous median sternoto-
my, had diabetes mellitus with an elevated serum creatinine
content, or had inadequate vascular access for postoperative
angiography were also excluded.
Randomization was stratified on the basis of whether or not
patients received aspirin therapy within the 5 days preceding
the operation or a nonsteroidal anti-inflammatory drug
(NSAID) within 3 serum half-lives before the operation (50%
in each group). The random code was generated in blocks
within clinical center and stratum. At all times, patients and
physicians were blinded as to randomization assignment.
Operative procedures. Anesthesia, CPB, and postopera-
tive intensive care procedures followed routine standards at
each study site. The heparin loading dose for CPB was at least
350 IU/kg, which was the total of that administered before
aortic cannulation plus the heparin added to the prime volume
of the CPB circuit. Additional heparin was given to maintain
a kaolin-activated clotting time above 400 seconds and to
maintain whole blood heparin levels of 2.7 units/mL or more
on the basis of a heparin-protamine titration test performed
with the use of a heparin measurement system (Hepcon/HMS
system, Medtronic HemoTec, Inc, Parker, Colo). Patients ran-
domly assigned to the aprotinin group received a loading dose
of 2,000,000 KIU of aprotinin, followed by continuous infu-
sion at a rate of 500,000 KIU/h. In addition, 2,000,000 KIU
of aprotinin was added to the CPB circuit prime.
At the termination of CPB, packed RBCs were adminis-
tered if the hematocrit value was less than 18%. Post-
operatively, homologous blood or packed RBCs were admin-
istered if the hematocrit value was less than 19%. Additional
transfusion was provided if warranted by the patient’s condi-
tion. The use of additional hemostatic agents (e -aminocaproic
acid or desmopressin) was permitted if postoperative bleed-
ing could not be controlled by other means. After the opera-
tion, all patients received aspirin in a daily dose of 325 mg
with the first dose administered via nasogastric tube 6 hours
after the operation.
Angiographic analysis. Angiography with non-ionic con-
trast material was performed shortly after the coronary oper-
ation. If serum creatinine levels were more than 1.9 mg/dL
within 2 days of scheduled imaging, angiography was post-
poned. Angiographic readings using the same criteria were
performed both at the Central Radiographic Laboratory at
Stanford University and at each clinical site. Readers at the
Central Radiographic Laboratory were blinded as to clinical
site and their interpretations. In case of a discrepancy be-
tween the 2 readings, an independent reader adjudicated.
If grafts could not be identified by selective injection of
graft stumps, then either aortography or selective injection of
native coronary arteries (to identify collateral filling of oc-
cluded arteries) was used to assess graft patency. Because the
particular adverse effect of aprotinin on graft patency being
studied was presumed to be thrombotic, kinks, valves, and
anastomotic stenoses were not considered as adverse events
in either group. Total occlusions of grafts either at their ori-
gin or anywhere beyond were considered to be thrombotic
events. In addition, a clearly evident thrombus within the
graft, obstructing at least 50% of the luminal diameter, was
interpreted as an occluding lesion (4 cases). Additional angio-
graphic assessments included measurement of the graft diam-
eter, the diameter of the distal vessel into which the graft was
inserted, and the classification of the territorial distribution of
the grafted distal native vessel as small, medium, or large.
Other graft features considered in the final analysis included
single graft versus sequential or Y grafts, the graft type (saphe-
nous vein or internal thoracic artery), and location of the distal
vessel grafted.
Detection of myocardial infarction. Blood samples for
creatine kinase (CK) and CK-MB were collected before the
operation, at the time of arrival in the postoperative care unit,
6, 12, 18, and 24 hours after the operation, and on postoper-
ative days 3, 5, and 7 or at hospital discharge. A standard 12-
lead ECG was acquired before the operation and on postop-
erative days 3, 5, and 7 or at hospital discharge. In patients
having a suspected ischemic cardiac event outside the proto-
col window, an ECG was performed and enzyme levels asso-
ciated with that event were examined.
Myocardial infarct events were determined on a blinded
basis by the core ECG Laboratory at St Louis University
Medical Center. All ECGs were classified according to the
Minnesota code.12-15 The diagnosis of definite myocardial
infarction was based on the following criteria: (1) the new
development of a 2-step worsening in Q wave according to
the Minnesota code, (2) the new development of persistent
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left bundle branch block patterns, or (3) the presence of acute
necrosis at autopsy. The diagnosis of probable myocardial
infarction was based on the presence of an abnormal postop-
erative cardiac enzyme profile (eg, CK-MB values > 120
units 6, 12, and 18 hours after the operation) or an abnormal
profile associated with Minnesota code 1-step Q-wave wors-
ening. The diagnosis of possible myocardial infarction was
made when the cardiac enzyme profile was abnormal (persis-
tent values > 100 units). The cardiac enzyme profile was con-
sidered nondiagnostic for myocardial infarction when all CK-
MB values were less than 100 units.
Data collection. Basic demographic and comprehensive
clinical variables were collected, including the type and num-
ber of CABGs placed, the medications (including all doses of
heparin and protamine with the time administered), blood or
blood products administered, the hemoglobin/hematocrit
measurements, activated clotting time and Hepcon heparin-
protamine titrations during the operation, the study drug
administration times, and emergency events. All adverse
events were recorded both during and after the operation.
Thoracic drainage volume was recorded for the first 6 hours
after patient transfer to the intensive care unit and then subse-
quently until removal of drains. The amounts of allogeneic
whole blood, RBCs, fresh frozen plasma, platelets, and cryo-
precipitate transfused were noted.
Statistical analyses. The primary outcome variable in this
study was the percentage of patients with one or more occlud-
ed distal saphenous vein graft anastomoses determined by
graft angiography. The study sample size was designed to
detect a 50% increase in the proportion of aprotinin-treated
patients with saphenous vein graft occlusions versus placebo
with 80% power using an expected placebo occlusion rate of
16% (1-tailed, a .05). Confidence intervals at the 90% level
were computed for the difference in by-patient saphenous
vein graft occlusion rates. By means of the observed placebo
closure rate and the confidence interval for the aprotinin-
minus-placebo difference in rates, conditional confidence
intervals for the aprotinin versus placebo odds ratio for clo-
sure also were computed.
For the primary, by-patient analysis, center and number of
distal anastomoses were the a priori stratification factors. The
by-graft covariate analyses included, but were not limited to,
preoperative aspirin or NSAID usage, US versus European
clinical sites (for regulatory purposes), and adherence or non-
adherence to the concomitant heparin protocol. Stepwise logis-
tic regression analysis of factors associated with saphenous
vein graft occlusion considered each distal anastomosis sepa-
rately. Stepwise regression analysis of factors contributing to
vein graft occlusion included the patient-, laboratory-, opera-
tive-, graft-, and medication-related features listed in Table I. In
addition, the regression analysis considered US versus
European site, patient’s date of operation within each center by
tercile, tercile of interval between operation and angiography,
heparin and protamine doses, and whether or not aprotinin-
containing blood was used for vein graft preservation.
Independent variables included demographic, clinical, labora-
tory, medication, and operative attributes. A P value of .15 was
used to identify those variables included in a model of saphe-
nous vein graft risk for occlusion. Risk ratios for the number of
graft occlusions and associated 90% confidence intervals were
computed for all patient subgroups, comparing aprotinin treat-
ment over placebo. The method of generalized estimating
equations was explored to accommodate multiple observations
within patients. The intra-patient correlations were found to be
sufficiently small such that independence of graft observations
was reasonable. Statistical analyses were conducted with the
use of SAS programs (SAS Institute, Inc, Cary, NC).
Results
A total of 870 patients were randomized by clinical
center by means of a computer-generated randomiza-
tion code: 436 patients to the aprotinin group and 434
patients to the placebo group. The study included 10
US sites, which randomized 471 (54%) of the patients
(range 2 to 95 patients per site), and 3 sites within
Israel and Denmark, which randomized 126 (14.5%),
168 (19.3%), and 105 (12.1%) patients.
The mean age of all randomized patients was 62
years, 87% were male, 63% had severe angina, 28% had
an ejection fraction below 0.50, and 36% had received
aspirin or an NSAID within 3 serum half-lives of the
drug (usually 2 days) before the operation (Table I). The
total number of grafts was 2928 with an average of 3.0
grafts per patient. An internal thoracic artery graft, usu-
ally to the left anterior descending artery, was inserted
in 90% of patients. No significant differences were
detected in any baseline characteristics among patients
randomized to aprotinin and placebo groups. Table II
outlines the reasons for exclusion from various analyses
and provides the number of patients assessable for eval-
uating blood loss/blood replacement, saphenous vein
graft occlusion, and myocardial infarction.
Blood loss and blood product replacement. Of the
870 randomized patients, 74 patients were excluded
from this analysis of blood loss and blood product
replacement because of additional intraoperative proce-
dures (n = 14), preoperative blood transfusion (n = 3),
other protocol deviations (n = 4), and confounding post-
operative events (n = 53) (Table II). In regard to the lat-
ter, 37 postoperative events were related to bleeding,
including 30 re-explorations and 7 episodes of gastroin-
testinal bleeding (Table II). Twenty-four of these 37
postoperative events occurred in the placebo group
compared with 13 in the aprotinin group (P = .07 by c 2
analysis).
Blood loss and blood product replacement results are
summarized in Table III. The aprotinin-treated patients
exhibited a 43% lower thoracic drainage volume and a
49% lower requirement for allogeneic RBC administra-
tion (through day 12) when compared with the placebo
group. In addition, the aprotinin-treated patients re-
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quired significantly fewer platelet transfusions, less
fresh frozen plasma, less cryoprecipitate, and fewer
additional hemostatic agents than did placebo recipi-
ents. No statistically significant differences were noted
in the use of heparin or protamine administered during
surgery between groups (Table III).
Angiographic results: Saphenous vein and inter-
nal thoracic artery grafts. Coronary arteriograms of
adequate quality to assess saphenous vein graft patency
were obtained a mean of 10.8 days after the operation
(range 0-91 days; median 7 days), with 85% completed
within 2 weeks of the operation. The clinical, laboratory,
and operative features of the 703 patients in whom
saphenous vein graft patency was assessable (80.8% of
all patients) did not differ markedly from those of the
134 not assessed (Table I). The non-assessed patients
were slightly older, had less total protamine, and had
lower preoperative hemoglobin values.
Table I. Characteristics of all patients and those included in the assessment of the saphenous vein grafts
Saphenous vein graft performed
Angiography Angiography 
All study patients not performed performed
Danish and 
Aprotinin Placebo All sites All sites US sites Israeli sites
Patient No. 436 434 134 703* 381 322
Preop ASA/NSAID (%) 50.1 50.0 53.0 49.4 62.2 34.2
Clinical features
Age (yr, mean ± SD) 61.8 ± 9.1 62.3 ± 9.1 64.3 ± 9.7† 61.8 ± 9.0† 61.6 ± 9.4 62.0 ± 8.6
Male (%) 87.4 86.9 85.1 88.3 90.6 85.7
Weight (kg, mean ± SD) 81.7 ± 14.1 83.3 ± 15.0 82.3 ± 14.9 82.5 ± 14.4 85.9 ± 15.0 78.5 ± 12.5‡
BSA (m, mean ± SD) 1.94 ± 1.8 1.96 ± 2.0 1.95 ± 2.0 1.95 ± 1.9 2.00 ± 1.9 1.89 ± 1.7‡
NYHA class III-IV (%) 62.2 64.5 68.7 62.7 73.8 49.7‡
MI ≤ 30 d preop (%) 11.7 14.3 16.4 12.7 19.2 4.97‡
LVEF ≤ 0.5 (%) 29.2 26.3 25.6 28.8 28.1 29.6
Adjunctive drugs
ASA within 2 days of operation 35.3 37.3 41.8 35.1 42.8 26.1‡
(%)
Total protamine (mg, 338 ± 115 337 ± 10.5 310 ± 115† 341 ± 109† 369 ± 105 309 ± 104‡
mean ± SD)
Total heparin (U, 59,200 ± 17,537 59,627 ± 15,571 59,567 ± 20,196 59,410 ± 16,002 56,560 ± 14,517 62,782 ± 17,015‡
mean ± SD)
Laboratory analyses
Preop PTT (s, mean ± SD) 31.6 ± 14.3 32.4 ± 16.6 34.0 ± 22.0 31.7 ± 14.0 36.1 ± 16.2 26.4 ± 8.2
Preop Hgb (g/dL, mean ± SD) 14.0 ± 1.2 14.0 ± 1.3 13.7 ± 1.4† 14.0 ± 1.3† 14.0 ± 1.4 14.0 ± 1.3
Preop creatinine (mg/dL, 1.13 ± 0.23 1.3 ± 0.21 1.15 ± 0.24 1.13 ± 0.22 1.11 ± 0.24 1.15 ± 0.19
mean ± SD)
Graft insertions (by patient)
Total/patient (mean ± SD) 3.0 ± 0.81 3.0 ± 0.9 3.2 ± 0.8 3.1 ± 0.8 3.1 ± 0.07 3.1 ± 0.8
SVG/patient (mean ± SD) 2.1 ± 0.83 2.1 ± 0.9 2.2 ± 0.8 2.1 ± 0.8 2.2 ± 0.8 2.1 ± 0.8
Y or sequential SVG (%) 24.1 22.7 26.1 23.9 31.2 15.2‡
ITA graft (%) 89.4 89.6 91.1 88.9 86.1 92.2
Total graft insertions (No.) 1474 1454 321 1734 990 744
Distal vessel ≤ 1.5 mm 54.1 51.8 59.4 56.5 54.3 59.4
(% of grafts)
Distal vessel quality:
Good (% of grafts) 46.0 46.4 44.7 45.6 56.5 31.3‡
Fair/poor (% of grafts) 54.0 53.6 55.3 54.4 43.5 68.7‡
Graft size:
Large (% of grafts) 12.6 14.0 16.7 14.8 11.8 18.7‡
Normal/small (% of grafts) 87.4 86.0 83.3 85.2 88.2 81.3‡
SVG, Saphenous vein graft; NSAID, nonsteroidal anti-inflammatory drug; ASA, acetylsalicylic acid (aspirin); BSA, body surface area; LVEF, left ventricular ejection
fraction; PTT, partial thromboplastin time; Hgb, hemoglobin.
*Thirty patients underwent angiography, but had no vein grafts.
†P < .01 when comparing angiography and no-angiography groups.
‡P < .01 when comparing US and European sites.
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Of the 703 patients with assessable saphenous vein
grafts, 15.4% of patients randomized to aprotinin had
one or more occluded vein grafts compared with a
10.9% occlusion rate in patients randomized to placebo
(Table IV). This 4.5% difference in graft occlusion
rates had a 90% confidence interval of 1.3% to 9.6%.
The risk ratio overall was 1.5 (90% CI, 1.1-2.1). These
raw data demonstrated a significantly higher rate of
graft occlusion for the aprotinin group (P = .03).
A secondary analysis of distal vein graft anastomoses
showed that 7.5% of distal anastomoses in the aprotinin
group were occluded compared with 4.8% of anasto-
moses in the placebo group (Table IV). This 2.7% dif-
ference in occlusion rates corresponded to a risk ratio
of 1.7 (90% conditional CI, 1.2-2.1). No significant dif-
ferences were seen in the very low occlusion rates
(aprotinin 1.8%; placebo 1.0%; P = .32) in the internal
thoracic artery grafts.
Angiographic results: US patients compared with
European patients. At Danish and Israeli sites, saphe-
nous vein graft occlusion occurred in 23.0% of apro-
tinin-treated patients compared with 12.4% of compa-
rable placebo-treated patients (risk ratio, 2.1; 90%
conditional CI, 1.3-2.9; Table IV). In contrast, at US
sites vein graft occlusion rates were comparable at
9.4% for aprotinin-treated patients and 9.5% for place-
bo-treated patients (risk ratio, 1.0; 90% conditional CI,
0.5-1.8). At the Danish and Israeli sites, saphenous vein
graft occlusion rates in both the aprotinin and placebo
groups improved from the initial enrollment tercile to
subsequent terciles (aprotinin, 34.5%-17.0%; placebo,
15.7%-10.9%).
Because of these geographic differences in saphe-
nous vein occlusion rates, patient characteristics listed
in Table I were compared between US and European
sites. Patients operated on at US sites weighed more
and had a larger body surface area than those at the
Danish and Israeli sites. US patients were more likely
to have had a myocardial infarction within the preced-
ing 30 days, had more severe angina, were more likely
to have taken aspirin within 2 days before the opera-
tion, had longer preoperative partial thromboplastin
times, and tended to have larger and better-quality distal
vessels than the European patients (Table I).
Of the 13 surgical sites, 5 used heparinized and apro-
tinin-containing blood from the aortic cannulation site
for flushing and preservation of the harvested vein.
These 5 sites included the 3 Danish and Israeli sites
(46% of study patients) and 2 small US centers (9% of
study patients). At the remaining 7 US sites (45% of
study patients), non-blood containing perfusate was
used. At 1 Israeli site during the initial third of patient
enrollment, blood for vein flushing and preservation
was obtained from the same central venous line into
which the aprotinin bolus and infusion had been admin-
istered. At this site, the saphenous vein graft occlusion
rate was 73% in aprotinin-treated patients during the
first third of the study, which significantly exceeded the
11% occlusion rate in placebo-treated patients. After
revision of procedures at this site, saphenous vein graft
occlusions in aprotinin-treated patients decreased to
14% compared with 3% in placebo-treated patients for
the remaining two thirds of the study.
Stepwise regression analysis of predictors of graft
occlusion. Variables predictive of increased graft
occlusion for aprotinin versus placebo were smaller
distal vessel size, lower total protamine dose, smaller
graft size, older age, lower ejection fraction, female
gender, no aspirin within 2 days before the operation,
Table II. Subject availability for outcome analysis
Patient No.
Aprotinin Placebo
Randomized patients 436 434
Analysis of blood loss and replacement 401 395
Exclusion for intraoperative protocol 13 8
deviation
Random code unblinded 1 2
Blood received preop or in prime fluid 3 0
Additional intraop procedure 8 6
Aprotinin discontinued 1 0
Exclusion for confounding postop event 22 31
Death within 6 h postop 1 1
Re-exploration/surgical bleeding 11 19
Additional postop surgical procedure 8 6
Gastrointestinal bleeding 2 5
Angiographic analysis of SVG patency 363 340
by patient
Exclusion: no SVG performed 13 17
Exclusion: death during hospitalization 5 6
for operation
Exclusion: no postop angiography performed 49 68
Exclusion: not all SVGs assessable 6 3
Angiographic analysis of SVG patency 897 837
by distal anastomosis
Exclusion: hospital death 5 6
Exclusion: no postop angiography 111 150
Exclusion: anastomosis not assessable 9 5
Angiographic analysis of ITA graft patency 326 304
by patient
Exclusion: no ITA graft with single 55 54
anastomosis performed 
Exclusion: death during hospitalization for 6 4
operation
Exclusion: no postop angiography performed 43 66
Exclusion: ITA graft not assessable 6 6
Analysis of myocardial infarction 410 421
Exclusion: inadequate ECG data 26 13
SVG, Saphenous vein graft; ITA, internal thoracic artery; ECG, electrocardiogram.
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and lower quality distal vessels (Table V, column 1).
These adverse predictors of graft occlusion were con-
sistently more prevalent in the Danish and Israeli
patients than in the US patients (Table I).
Table V summarizes the effect of patient- and graft-
related predictors of saphenous vein graft occlusion on
graft occlusion associated with aprotinin versus place-
bo treatment. Saphenous vein grafts placed at Danish
and Israeli sites had higher rates of occlusion with
aprotinin than at US sites (European sites, 11.6%; US
sites, 4.4%; Table V, columns 3 and 4). Similarly,
saphenous vein grafts placed during the initial tercile of
the study had higher rates of occlusion (initial tercile:
9.8%; later terciles: 6.0%; Table V, columns 3 and 4).
The observed univariate (unadjusted) risk ratio for graft
occlusion with aprotinin versus placebo treatment was
greater for most patient subgroups of the Danish and
Israeli patients compared with the ratios in the US
patients (Table V, columns 5, 6, and 7).
The 3 European sites had a significantly higher pro-
portion of patients with adverse graft and distal vessel
features, which were associated with a higher propor-
tion of graft occlusion in aprotinin-treated patients than
in placebo-treated patients. When the risk ratio for graft
occlusion by aprotinin versus placebo was adjusted by
stepwise logistic regression analysis for all predictors
of graft occlusion in both US and European patients,
the predictive power of each variable was attenuated
(Table V, column 8; Fig 1). The adjusted risk ratio for
vein graft occlusion at Danish and Israeli sites was 1.7
versus 0.7 for US sites (Table V, column 8) and for the
overall study the adjusted risk ratio was 1.1. The
adjusted confidence intervals for risk of graft occlusion
with aprotinin treatment versus placebo treatment
remained above 1.0 for female gender, for distal vessels
of poor quality, and for distal vessel sizes below 1.5
mm (Table V, column 9; Fig 1). Fig 2 summarizes the
effect of aprotinin versus placebo treatment on risk
ratios after adjustment for selected important variables.
Bifurcation or sequential vein grafts were used in
31% of patients at US sites compared with 15% at
Danish and Israeli sites (P = .001). Covariate analysis
Table III. Analysis of blood loss and replacement
Aprotinin (n = 401) Placebo (n = 395) P value
Surgical factors
Duration of operation (h, mean ± SD) 3.5 ± 1.5 3.6 ± 1.4 .36
Total bypass time (min, mean ± SD) 93.2 ± 53.8 92.9 ± 54.6 .89
Closure time (min, mean ± SD) 46.4 ± 32.94 50.9 ± 33.7 .001
Heparin during surgery (U/kg, mean ± SD) 687 ± 298 687 ± 302 .99
Protamine during surgery (mg, mean ± SD) 331 ± 154 328 ± 157 .68
Blood loss
Total thoracic drainage (mL, mean ± SD) 664 ± 1009 1168 ± 1022 <.0001
Postop drainage—mL/initial 6 h, mean ± SD) 228 ± 459 491 ± 465 <.0001
Change in hemoglobin from hospital entry to discharge (g/dL, mean ± SD) –2.7 ± 8.0 –3.6 ± 8.2 .003
Time in hospital (d, mean ± SD) 7.6 ± 8.5 7.8 ± 8.6 .60
Donor replacement through day 12
Patients requiring any blood product (%) 40 58 <.0001
Patients requiring donor RBCs (%) 38 54 <.0001
All allogeneic blood/blood products required (U/patient, mean ± SD) 1.1 ± 2.2 3.8 ± 7.3
5, 50, 95 percentiles 0, 0, 4.5 0, 2, 18 <.0001*
Packed RBCs (mL/patient, mean ± SD) 296 ± 500 575 ± 790
5, 50, 95 percentiles 0, 0, 1400 0, 300, 2100 <.0001*
Platelets (U/patient, mean ± SD) 0.1 ± 1.1 1.2 ± 3.5
5, 50, 95 percentiles 0, 0, 0 0, 0, 10 <.0001*
Fresh frozen plasma (U/patient, mean ± SD) 0.2 ± 0.8 0.5 ± 1.7
5, 50, 95 percentiles 0, 0, 2 0, 0, 4 <.0001*
Cryoprecipitate (U/patient, mean ± SD) 0 ± 0.0 0.4 ± 2.1
5, 50, 95 percentiles 0, 0, 0 0, 1, 5 <.0001*
Donor RBCs (U/patient)
All patients (mean ± SD) 0.8 ± 1.3 1.6 ± 2.0
5, 50, 95 percentiles 0, 0, 3 0, 1, 5 <.0001*
High-risk patients (mean ± SD) 0.9 ± 1.3 1.6 ± 2.0
5, 50, 95 percentiles 0, 0, 3.5 0, 1, 6 <.0001*
Low-risk patients (mean ± SD) 0.7 ± 1.3 1.6 ± 2.1
5, 50, 95 percentiles 0, 0, 3 0, 1, 5 <.0001*
RBCs, Red blood cells. 
*Data were analyzed nonparametrically with rank analysis of variance.
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revealed that these grafts were less likely to occlude
than single grafts, regardless of treatment group. The
distal insertions of bifurcation or sequential grafts were
4 times less likely to occlude than single insertion vein
grafts in aprotinin-treated subjects and 9 times less
likely to occlude in placebo-treated patients (Table V,
columns 3 and 4).
Lower protamine doses were independently associat-
ed with a greater likelihood of graft occlusion and also
with a greater adverse effect of aprotinin on graft
patency (Table V). The total protamine dose was high-
ly correlated with the total heparin dose. This reflects
the use of the heparin-protamine titration test results
obtained at the end of CPB to determine protamine
dosing. The lower mean protamine dose in the Danish
and Israeli patients, despite higher mean heparin doses
associated with this patient population (Table I), may
reflect a longer duration of procedure, relative heparin
resistance caused by greater preoperative use in unsta-
ble patients, lower levels of circulating heparin at the
end of bypass, or other indeterminate factors.
Regression analysis found no relation between
saphenous vein graft occlusion and the extent of blood
loss or replacement. In addition, we modeled risk for
saphenous vein graft occlusion using predictors of graft
occlusion and found that the hemostatic benefit of
aprotinin in reducing blood loss and the need for blood
product replacement was independent of the probabili-
ty for graft occlusion.
Clinical events. Six hospital deaths were observed in
the aprotinin group (1.4%), whereas 7 hospital deaths
occurred in the placebo group (1.6%). Serious adverse
events (including those leading to death) occurred in
18% of aprotinin-treated patients (77/436) and 17% of
placebo-treated patients (73/434) and were almost
entirely cardiorespiratory in origin. The prevalence of
serious bleeding was 1% in aprotinin-treated patients
(5/436) compared with 5% in placebo-treated patients
(22/434; P = .001).
No statistically significant differences were noted
between the 2 treatment groups in the prevalence of def-
inite, probable, or possible myocardial infarctions based
on blinded readings from the core ECG laboratory
(aprotinin: 2.9%; placebo: 3.8%; Table VI). Eighty-
eight percent of patients in both the aprotinin and place-
bo groups had no evidence of myocardial infarction. Of
the 668 patients with both ECG and angiographic data
available, 40% of the 55 patients with a definite or prob-
able myocardial infarction had an occluded saphenous
vein graft; however, in these patients, there was no sig-
nificant difference in occlusion rates between the apro-
tinin-treated and placebo-treated patients (P = .50;
Table VI). Of these same 668 patients, 24% of 90
patients with 1 occluded graft or more had an infarction,
but again, there was no significant difference in infarc-
tion rates between the aprotinin and placebo groups (P
= .34, Table VI). Logistic regression analyses showed
no interaction of treatment with patient subgroups and
Table IV. Analysis of graft occlusion
A-P difference Risk ratio for 
Aprotinin Placebo (CI) occlusion (A/P) 90% CI P value
Patients with any occluded SVG 
(aprotinin; placebo)
All sites
All patients (363; 340) 15.4 10.9 4.5 (1.3; 9.6) 1.5 1.1-2.1 .03
US sites
All patients (202; 179) 9.4 9.5 –0.1 (–3.8; 5.9) 1.0 0.5-1.8 .72
Surgery in first entry tercile (64; 66) 7.8 12.1 –4.3 (–13.7; 7.0) 0.6 0-1.7 .60
Surgery in second/third entry tercile (138; 113) 10.1 8.0 2.1 (–2.8; 10.1) 1.3 0.6-2.6 .35
Israeli and Danish sites
All patients (161; 161) 23.0 12.4 10.6 (3.4; 17.3) 2.1 1.3-2.9 .01
Surgery in first entry tercile (55; 51) 34.5 15.7 18.8 (10.6; 35.3) 2.8 2.1-6.4 .002
Surgery in second/third entry tercile (106;110) 17.0 10.9 6.1 (–2.5; 13.6) 1.7 0.8-2.6 .25
Occluded distal SVG insertions (aprotinin; placebo)
All sites
All SVG insertions (897; 837) 7.5 4.8 2.7 (0.9; 4.8) 1.7 1.2-2.1 .02
Single SVG (677; 656) 9.2 5.9 3.3 (0.7; 5.6) 1.6 1.1-2.1 .03
Sequential SVG (220; 181) 2.3 0.6 1.7 (–1.2; 3.0) 4.2 0.0-5.8 .49
Patients with occluded ITA grafts 
(single grafts only, aprotinin; placebo)
All sites
All patients (326; 304) 1.8 1.0 0.8 (–0.7; 2.7) 1.9 0.3-3.8 .32
Confidence interval (CI) is conditional on observed placebo rate. A, Aprotinin; P, placebo; SVG, saphenous vein graft; ITA, internal thoracic artery.
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no overall effect of treatment on perioperative definite
or probable myocardial infarction rates.
Discussion
When administered to patients undergoing CPB
surgery, aprotinin is consistently associated with
decreased fibrinolysis and reduced bleeding in the peri-
operative period. However, reduction in fibrinolysis
could potentially increase the risk of thrombus forma-
tion and perioperative myocardial infarction. This double-
blinded, randomized study was undertaken in a suffi-
ciently large number of subjects, using blinded readings
at a core laboratory, and applying uniform entry and
interpretation criteria to evaluate the safety of aprotinin
in terms of its effect on graft patency. Secondary analy-
ses of differences among clinical site procedures and
Table V. Analysis of the interaction between variables predictive of saphenous vein graft occlusion and the effect of
aprotinin versus placebo on graft occlusion
Risk ratio for occlusion (aprotinin versus placebo)
Observed Adjusted for all 
occlusion rates (%) Observed predictive variables 
All patients
Variables predictive of P value:
SVG occlusion drug-by-covariate Danish and 
(No. of grafts) interaction Aprotinin Placebo All patients US patients Israeli patients Risk ratio 90% CI 
[1] [2] [3] [4] [5] [6] [7] [8] [9]
Site location NS
All sites (1734) 7.5 4.8 1.7 1.1 2.1 1.1 0.6-1.8
US sites (990) 4.4 4.0 NA 1.1 NA 0.7 0.4-1.3
Danish and Israeli sites (744) 11.6 5.8 NA NA 2.1 1.7 0.9-3.0
Enrollment tercile NA
First (594) 9.8 5.5 1.9 1.0 2.3 1.2 0.7-2.0
Second/third (1140) 6.0 4.0 1.6 1.4 1.9 1.0 0.6-1.8
Gender .06
Female (187) 20.7 4.2 5.9 * 6.1 5.3 1.8-15.8
Male (1547) 5.7 4.6 1.3 1.0 1.6 0.9 0.5-1.5
Age .07
>62 y (841) 8.4 3.8 2.3 1.4 2.3 1.6 0.8-3.1
≤62 y (887) 6.7 4.9 1.4 1.2 2.0 0.7 0.4-1.3
LVEF .06
‡ 0.50 (1201) 6.9 5.0 1.4 1.2 1.5 0.8 0.5-1.5
<0.50 (523) 8.1 3.4 2.5 1.4 4.2 1.8 0.8-4.5
ASA ≤2 d of operation .05
Yes (628) 5.0 1.8 1.1 1.1 1.1 0.6 0.3-1.6
No (1106) 8.5 4.4 2.0 1.3 2.8 1.4 0.8-2.5
Graft type NA
Single (1333) 8.9 5.6 1.6 1.1 2.0 1.1 0.7-2.0
Y or sequential (401) 2.3 0.6 4.2 3.0 † 0.8 0.5-1.4
Distal vessel size .06
≤1.5 mm (976) 10.8 5.3 2.2 1.7 2.5 1.9 1.2-3.2
>1.5 mm (752) 2.4 3.5 0.7 0.3 1.1 0.5 0.2-1.2
Distal vessel quality .08
Fair/poor (938) 11.4 5.5 2.2 1.8 2.6 1.9 1.1-3.3
Good (787) 2.3 3.4 0.7 0.6 0.7 0.5 0.3-1.1
Graft size .09
Small/medium (1463) 7.5 4.5 1.7 1.4 2.1 1.2 0.7-2.2
Large (254) 5.9 4.5 1.3 0.0 2.3 0.5 0.2-1.2
Total protamine dose .07
<Mean = 342 mg (914) 10.6 5.5 2.0 3.3 1.9 1.8 0.8-3.7
>Mean = 342 mg (820) 5.4 4.0 1.4 0.9 2.3 0.6 0.3-1.1
NA, Not applicable. For column 2, NA indicates that the interaction was not selected for inclusion in the statistical model (P < .15). SVG, Saphenous vein graft; LVEF,
left ventricular ejection fraction; ASA, acetylsalicylic acid (aspirin).
*Risk ratio is infinite because no placebo events exist; aprotinin occlusion rate = 8.3%.
†Risk ratio is infinite because no placebo events exist; aprotinin occlusion rate = 1.9%.
724 Alderman et al The Journal of Thoracic and
Cardiovascular Surgery
November 1998
patient and graft characteristics revealed important
considerations when aprotinin is administered.
Blood loss and blood product replacement. This
study confirms the efficacy of a high-dose aprotinin
regimen in reducing both blood loss and the require-
ment for allogeneic blood transfusion. Aprotinin elicit-
ed a significant reduction in the total thoracic drainage
volume, the magnitude of which was comparable with
that reported previously by Lemmer and colleagues.8,9
Aprotinin decreased the need for allogeneic RBC trans-
fusions and reduced the total donor exposures per
patient to fresh frozen plasma and cryoprecipitate. The
present study demonstrated a 40% transfusion rate for
aprotinin-treated patients versus a 58% rate for place-
bo-treated patients. This finding is consistent with ear-
lier reports showing that 34% to 38% of aprotinin
recipients versus 52% to 55% of placebo recipients
required blood transfusions.8,9 Moreover, aprotinin
treatment was associated with a 47% reduction in reop-
eration for bleeding (11 vs 19 patients).
Angiographic results: Influence of graft and
recipient coronary vessel characteristics. Prior stud-
ies of early graft occlusion, generally conducted with
smaller numbers of subjects and nondefinitive imaging
methods, have shown no adverse effect of aprotinin on
clinical events or graft patency.3,8,11 The overall results
of this graft patency investigation found an increased
probability of saphenous vein graft occlusion with
aprotinin administration when analyzed on both per-
patient and per-graft bases. However, secondary analy-
ses revealed a significant interaction between certain
patient, vessel, and graft characteristics that were pre-
dictive of graft occlusion in both aprotinin and placebo
groups and associated with an adverse effect of apro-
tinin on graft patency. Multiple graft and recipient
coronary vessel characteristics are known to affect
saphenous vein graft patency, including the quality of
the vein (varicosities, thickened wall) and the small
size (especially <1.5 mm in diameter) and poor quality
of the recipient vessels.16-22
The occlusion rate with aprotinin treatment for vein
grafts to vessels less than 1.5 mm in diameter was 10.8%
in this study, which compares favorably with the 17.9%
occlusion rate previously observed in non–aprotinin-
treated patients 8 to 28 days after the operation.16 This
comparison of vein graft occlusion is based primarily on
grafts to the circumflex and right coronary vessels
because vein grafts comprise only 10% of grafts to the
anterior descending artery. Similarly, the 11.4% occlu-
sion rate in vessels of poor quality with aprotinin use
compares favorably with the occlusion rates of vein grafts
to the right and circumflex coronary arteries—27.6% for
poor-quality and 15.4% for good-quality distal vessels, as
previously reported by Paz and associates.16
These adverse graft and distal vessel characteristics
were more prevalent in patients enrolled at the Danish
and Israeli sites than in those enrolled at the US sites
Fig 1. The effects of aprotinin compared with placebo treat-
ment after adjustment for clinical, surgical, and angiographic
variables are shown as risk ratios (diamonds) and 90% confi-
dence intervals (horizontal lines) for saphenous vein graft
occlusion. A log scale is used. Selected variables shown in
Table V are plotted. A ratio greater than 1.0 denotes a higher
risk for graft occlusion with aprotinin than with placebo treat-
ment. LVEF, Left ventricular ejection volume; ASA, acetyl-
salicylic acid (aspirin); SVG, saphenous vein graft.
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Fig 2. The effects of aprotinin compared with placebo treatment before and after adjustment with logistic regres-
sion model are shown as risk ratios (diamonds) and 90% confidence intervals (horizontal lines) for saphenous
vein graft occlusion. A log scale is used. Clinical variables include age, gender, clinical site, tercile of study entry
date, and aspirin use before the operation. Surgical and angiographic variables include left ventricular ejection
fraction, graft type and size, distal vessel quality and size, and total protamine dose. A ratio greater than 1.0
denotes a higher risk for graft occlusion with aprotinin than with placebo treatment.
Table VI. Prevalence of myocardial infarction in aprotinin- and placebo-treated patients
Aprotinin patients Placebo patients
Assessable No. (%) Assessable No. (%) P value
MI*
Definite MI 410 12 (2.9) 421 16 (3.8) .47
Definite or probable MI 407 35 (8.6) 418 38 (9.1) .77
Definite, probable, or possible MI 408 50 (12.3) 418 50 (12.0) .93
Definite, probable, or possible MI
US sites 222 22 (9.9) 227 31 (13.7) .20
Danish and Israeli sites 186 28 (15.1) 191 19 (10.0) .13
Combined analysis of MI and graft occlusion
Patients with assessable SVGs and ECG data 340 328
Patients with an occluded SVG 54 36
Patients with an occluded SVG and an MI 11 (20.0) 11 (31.0) .34
Patients with a definite or probable MI 30 25
Patients with an MI having an occluded SVG 11 (37.0) 11 (44.0) .50
MI, Myocardial infarction; ECG, electrocardiogram; SVG, saphenous vein graft.
*Myocardial infarction was diagnosed on the basis of an electrocardiogram and the cardiac enzyme profile.
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and account for the higher graft occlusion in both treat-
ment groups (Table IV). The difference was much more
prominent when comparing total graft occlusions for
aprotinin-treated patients (aprotinin, European sites:
11.6%; aprotinin, US sites: 4.4%) than for placebo-
treated patients (placebo, European sites: 5.8%; place-
bo, US sites: 4.0%; Table V). One explanation for these
differences may be that the Danish and Israeli patients
had more advanced disease or a somewhat larger num-
ber of graft insertions per patient with a greater pro-
portion inserted into smaller distal vessels.
Angiographic results: Influence of surgical tech-
niques, aprotinin administration, and monitoring.
The site-by-site analyses, entry tercile analyses, and
procedure questionnaires suggested that differences in
saphenous vein harvesting techniques, aprotinin
administration, and heparin monitoring may have had
an effect on graft occlusion. Saphenous vein grafts pre-
served with blood-containing solutions appeared more
likely to occlude than vein grafts preserved with
non–blood-containing colloid (aprotinin, 9.3%; place-
bo, 4.8%). At the Danish and Israeli sites, which all
used blood-containing perfusate, a higher rate of vein
graft occlusion was observed with aprotinin treatment
than with the use of placebo (aprotinin, 11.6%; place-
bo, 5.8%). This effect was not observed at the single
US site that also used blood-containing perfusate
(aprotinin, 1.0%; placebo, 1.1%). However, the exis-
tence of a definitive relationship between the nature of
the perfusate and the aprotinin effects on graft patency
cannot be concluded because of the confounding statis-
tical effect of study center.
Regardless of the surgical technique used for vein
harvesting, endothelial disruption, denudation, and cel-
lular dysfunction occur.23-27 Blood-containing solu-
tions have been reported to enhance endothelial preser-
vation when compared with normal saline solution,27
but they appear to be no better or worse than balanced
salt solutions.22,28 It has been suggested that the inter-
action of platelet aggregates, leukocytes, and fibrin
with damaged areas of endothelium, which have been
found more commonly on the endothelium of veins
prepared with blood, further worsens the endothelial
injury.22,29,30 Because aprotinin preserves platelet func-
tion and has antifibrinolytic properties, blood-contain-
ing preservation solutions that also contain aprotinin
could lead to higher early graft closure rates.
Anticoagulation achieved during cardiac operations
is commonly assessed from clotting times, with addi-
tional heparin administered accordingly. However,
aprotinin inhibits contact activation, such that, when
the celite-based activated clotting time is used, an arti-
factually prolonged clotting time results. Therefore
heparin administration based on celite clotting times
may result in inadequate anticoagulation and conse-
quent thrombotic complications in aprotinin-treated
patients. To avoid such complications in this study, we
measured heparin levels directly by protamine titration.
At a few sites, the results of activated clotting time
measurements obtained during aprotinin use may have
influenced the amount of additional heparin adminis-
tered during surgery, potentially adversely affecting
graft patency rates in aprotinin-treated patients.
The earlier observations by Levy and colleagues,10 that
significant differences in activated clotting times may be
obtained despite similar heparin concentrations in apro-
tinin-treated patients, emphasizes the importance of con-
sistency in heparin dosing among treatment groups when
comparing the risk for graft occlusion in aprotinin- and
placebo-treated patients. When anticoagulation practices
were guided by both activated clotting times and heparin
concentrations, and the latter were maintained at 2.7
units/mL or more (direct measurement), no difference in
the occurrence of perioperative myocardial infarction in
aprotinin versus placebo recipients was observed.
Clinical events. Cosgrove and associates7 previously
reported data that showed a 12.4% prevalence of
myocardial infarction in 113 aprotinin-treated patients
compared with a 7.1% prevalence in 56 placebo-treated
patients undergoing a second CABG (P = .298). Post-
mortem examinations in 7 of 13 deaths at unspecified
intervals after the operation revealed thrombi in half of
the vein grafts in 4 aprotinin-treated patients compared
with none in 3 placebo-treated patients. In contrast, the
results of the current study of 831 patients with assess-
able ECGs showed that aprotinin did not adversely
influence the prevalence of myocardial infarction or
mortality, irrespective of which definition for myocar-
dial infarction was used.
In a more recent multicenter study of repeat surgery
for elective myocardial revascularization,10 definite or
probable myocardial infarction occurred in 20 of 70
patients (29%) receiving high-dose aprotinin and in 19
of 65 control patients (29%). In our study of primary
coronary surgery, the occurrence of myocardial infarc-
tion according to the same core laboratory and ECG
criteria was substantially lower, with an 8.6% infarc-
tion rate for aprotinin-treated patients and a 9.1% rate
for placebo-treated patients. Additionally, we observed
a definite myocardial infarction in only 3.8% of place-
bo-treated patients, whereas it was seen in 12% of the
placebo-treated patients undergoing repeat CABG.10
Summary and conclusions
This study documented that high-dose aprotinin, ad-
ministered prophylactically to patients having primary
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CABG, reduced blood loss, donor blood requirement,
and the need to re-explore to stop bleeding without any
increased risk of mortality or myocardial infarction.
Saphenous vein graft patency in the overall study pop-
ulation indicated a higher occlusion rate after aprotinin
than placebo. In US patients, in contrast to the
European patients, the occlusion rate was essentially
the same for aprotinin and placebo. Secondary analyses
confirmed that patient and anatomic characteristics
known from previous studies to promote graft occlu-
sion similarly were found to do so in this study. In the
presence of such characteristics, aprotinin was associ-
ated with an increased rate of early vein graft occlu-
sion. The use of aprotinin in patients having primary
CABG, in whom the primary distal target vessels are
less than 1.5 mm in diameter or of poor quality, may
adversely affect patency, which may be mitigated by
sequential grafting. Moreover, blood-containing preser-
vation solutions for saphenous vein harvest techniques
should be collected from the patient before the admin-
istration of aprotinin. Nevertheless, the interaction
between aprotinin and predictors of graft occlusion did
not compromise the beneficial effect of aprotinin in
reducing blood loss or transfusion requirements.
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Discussion
Dr Stephen Westaby (Oxford, United Kingdom). There
has been intense interest in the antifibrinolytic agent aprotinin
since the description of its hemostatic effects in 1984.
Perhaps my first comment should be that fibrinolysis is a nec-
essary process to maintain blood vessel patency in the face of
thrombin generation during any type of operation. In moder-
ately hypothermic coronary surgery, the difference in blood
loss between aprotinin use or nonuse is usually in the region
of 250 mL. This is well documented, and further studies are
not necessary. 
The continuing controversy is focused on the adverse
effects of aprotinin and whether use of this agent should be
extended from high-risk operations to routine CABG. 
The question, does aprotinin promote graft occlusion, is a
very important one. Most centers have anecdotal cases of
thrombosis, but this is the first international multicenter trial
designed specifically to address the graft occlusion issue
definitively by graft angiography. 
As is inevitable with ambitious multicenter projects, there
were some problems with design and compliance of the study. 
First, this is a historic study because it ended in 1996 and
more than 2 years have been required to analyze the data. I
would suggest that the coronary population is changing with
a rise in interventional cardiology, and most patients now
have progressively worse vessels. 
I identified a number of problems. There were different
methods of vein graft preparation from center to center, and
in 1 case, in an Israeli site, this led to a change in study pro-
tocol. Was a cell salvage device used in any of these patients
and did blood cardioplegic solution contain aprotinin? 
The problems of compliance were interesting. Twenty per-
cent did not go on to graft angiography. Could you say how
many of those sites were US, Danish, or Israeli? 
Much of the data subanalysis was based on inexact science,
because distal vessel size is underestimated when flow is
restricted, and of course when the grafts were blocked and
there was a proximal anastomosis, flow was restricted. The
data were analyzed by the interested pharmaceutical compa-
ny. Did the findings, as opposed to the study design, direct the
type of analysis used? 
I looked carefully at the difference between the sites. In the
US, there were 10 sites with a mean number of patients of 47.
The range was 2 to 95 patients, which means that at least in 1
center only 1 patient was randomized each year. I think if you
have a national CABG rate of more than 1000 per year, and
most of the patients are men, and you select the patients for a
trial like this, the graft occlusion rates are bound to be low.
In contrast, the 3 non-European centers randomized at least
133 patients each, there was a lower intervention rate in
Europe, and more were female patients. This gave a differ-
ence in occlusion rates of 23 to 12, which I think is very sig-
nificant. Subanalysis of graft occlusion rates shows that apro-
tinin definitely promotes graft occlusion in women, who had
a 5-fold increase over placebo, as well as in smaller vessels
and those with distal poor vessels. 
My impression from a European perspective is that now
virtually every patient left over by the interventional cardiol-
ogist has 1 or more of the high-risk variables. In very few
patients are all the coronary arteries larger than 1.5 mm or
free from distal disease, and certainly most patients referred
for coronary reoperation have the adverse characteristics that
tend to promote graft occlusion with aprotinin. 
The most important question about this study is whether
the use of aprotinin is justified in CABG given the risks of
graft occlusion documented by this study. Most patients will
recover from a low hematocrit value without blood transfu-
sion, but residual coronary occlusions leave the patient at risk
from late ischemic events.
Dr Rich. With respect to the cell salvage device, it was not
used during operations at my center. Blood cardioplegic solu-
tion would by default have aprotinin in it because we mix it
as we proceed through the operation. I do not know what each
center does with respect to the mixing of their blood cardio-
plegic solution, and these centers have not been asked that
question specifically. We did not ask the question you raised
about the use of aprotinin-containing blood for saphenous
vein flushing, and it is reported in the manuscript.
I cannot tell you the percentage of patients who did not
undergo angiography at the Danish and Israeli sites versus the
others. Finally, with respect to the statistical analysis, the
findings did not direct the type of analysis performed. It was
predetermined and set before the onset of the trial. Dr
Alderman at Stanford was very happy with the intent and
design of the statistical analysis and had oversight with re-
spect to it.
Mr Ben Bidstrup (Townsville, Australia). I think your
group is to be congratulated for undertaking such a large
study. It is often very difficult to get a cardiologist to look at
our patients in the postoperative period, and I am sure
patients who have an angioplasty and have a problem proba-
bly have multiple catheterizations, often in the first few
weeks after their procedure. 
This study highlights significant differences between the
European and the US populations. This can be extrapolated to
other countries in the world, such as Australia. Many of us
outside of the US have waiting lists measuring months. The
majority of our patients have been waiting for quite some
time. They have many of those unfavorable characteristics
that this study has identified. In a way, it is somewhat grati-
fying that the earlier studies such as the one which I present-
ed a few years ago at this meeting and that of Dr Lemmer,
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which showed a slight trend toward increased graft occlusion
in the saphenous veins, have been confirmed by the ultimate
gold standard. 
I have a couple of questions that I would like you to address.
Was there any difference in the number of grafts placed on the
patients between the US and the European sites? I wonder
whether more grafts are placed to small vessels in the European
groups, which may have made a difference in graft occlusion. 
Perhaps you would speculate on another point. Our cardi-
ologists who will do an angioplasty of the left anterior de-
scending coronary artery and say, “I will lose the diagonal,
but that won’t matter very much; he’ll have a little infarct and
he won’t have any angina.” Would you look further at this
patient population and see whether in the long-term there is
going to be any difference in outcome, such as recurrence of
symptoms or need for reoperation?
Dr Rich. I do not know the answer to the number of grafts,
Europe versus US. My impression is that there was not a
major difference. A follow-up study is already in progress;
we have already evaluated patients who have been enrolled
for 2 years for recurrence of angina, recurrence of event,
reoperative rates, need for angioplasty, and treatment of angi-
na with medical therapy. I have been very satisfied and will
be happy to see all the other centers’ results. It will be gratify-
ing to show this to the cardiologists. We have literally no need
for reoperation or interventional therapy. Among 72 patients,
we have had 1 patient with angina and 4 late deaths, equally
divided between aprotinin and placebo groups. My sense is
that we are not having a lot of late problems with aprotinin,
but the results verify that surgery is probably a good inter-
vention for patients with coronary disease still.
Dr Randall B. Griepp (New York, NY). I am sorry. I have a
problem with the analysis here. I can understand that there
were more high-risk patients for graft occlusion in the
European group than in the American group, and when you
look at the distribution of patients, the difference in graft
patency between the 2 geographical groups disappears. But
with a prospective, randomized allocation of patients in the
European as well as in the American group, the poor-risk
patients for graft occlusion should have been distributed
equally into aprotinin and placebo groups both in Europe and
in the USA. How can you, then, with a post hoc analysis, go
back and do away with the results that were built into the
prospective experimental design? Perhaps you can explain.
Dr. Rich. I agree. One should not go through a study like
this and then try to explain away the results. This can be done
with virtually any study. However, we can evaluate the US
patients and say there is no difference. If we then evaluate the
European patients and see that there are differences, we then
analyze the reasons for the differences and look for high risks.
Fortunately, we can control for these high risks. If we then
combine the data and do a risk stratification, the differences
become insignificant. Therefore let us not deny the results that
are there and see that there are anatomic and patient charac-
teristics that really do promote graft occlusion, with or with-
out aprotinin use, and use aprotinin in a logical way.
